Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nakanishi's Debt-to-Equity or its related term are showing as below:
FRA:6SN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.28
Current: 0.28
During the past 13 years, the highest Debt-to-Equity Ratio of Nakanishi was 0.28. The lowest was 0.00. And the median was 0.00.
FRA:6SN's Debt-to-Equity is ranked worse than 55.22% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:6SN: 0.28
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nakanishi Debt-to-Equity Related Terms
Nakanishi Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nakanishi's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6SN vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Nakanishi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nakanishi Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nakanishi's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nakanishi's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nakanishi (FRA:6SN) has a Debt-to-Equity of 0.28 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nakanishi and its competitors. According to the industry distribution chart, Nakanishi ranks #386 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 55.2%.
Is Nakanishi's Debt-to-Equity too high?
Nakanishi's current Debt-to-Equity is 0.28. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Nakanishi's value of 0.28 is 21.7% above this industry median. Based on the distribution chart, Nakanishi ranks #386 out of 699 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nakanishi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Nakanishi's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nakanishi ranks #386 out of 699 companies for Debt-to-Equity. This places Nakanishi in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Nakanishi's value of 0.28 is 21.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nakanishi's current Debt-to-Equity of 0.28 is 21.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nakanishi and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nakanishi's current Debt-to-Equity is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nakanishi stock overvalued right now?
Nakanishi (FRA:6SN) has a current Debt-to-Equity of 0.28. The stock's GF Value™ is €16.85, compared to a current price of €16.50 — trading 2.1% below its estimated fair value. The current Debt-to-Equity is 0.28 and 21.7% above the Medical Devices & Instruments industry median of 0.23. Nakanishi's overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nakanishi (FRA:6SN), the current Debt-to-Equity is 0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nakanishi (FRA:6SN) Overvalued in 2026?
Based on GuruFocus' analysis, Nakanishi stock appears to be undervalued.
The current stock price of €16.50 is trading 2.1% below its estimated GF Value™ of €16.85.
Key valuation signals for FRA:6SN:
Debt-to-Equity: 0.28
GF Value™: €16.85 vs. price of €16.50 (2.1% below fair value)
Industry Position: 21.7% above the Medical Devices & Instruments median (#386 of 699)
No single metric tells the full story. See the FRA:6SN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nakanishi Inc manufactures high-speed rotary cutting technology for the dental industry and the medical industry more broadly. The company distributes its products to countries internationally, earning its key revenue overseas. The company operates via three business segments. The dental product segment manufactures and sells handpieces for dental treatment, mechanical micro motors and handpieces as well as handpieces for surgeries. The surgical business segment manufactures and sells grinders for manual works and spindles for machinery attachment. The Machinery business segment provides inspection and repair services for its dental and medical equipment and general industrial cutting and grinding equipment.
93GF Score
Get the complete analysis for FRA:6SN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6SN has been successfully added to your 
